



Health
Canada

Santé
Canada

Therapeutic Products Directorate

Drug Submission Performance Quarterly Report

April – June

2018



Canada

Health Canada is responsible for helping Canadians maintain and improve their health. It ensures that high-quality health services are accessible, and works to reduce health risks.

Également disponible en français sous le titre :

Direction des produits thérapeutiques – Rapport trimestriel du rendement des présentations de drogue – avril – juin 2018

To obtain additional information, please contact:

Health Canada

Address Locator 0900C2

Ottawa, Ontario, K1A 0K9

Tel.: 613-957-2991

Toll free: 1-866-225-0709

Fax: 613-941-5366

TTY: 1-800-465-7735

E-mail: hc_publications-publications.sc@canada.ca

© Her Majesty the Queen in Right of Canada, as represented by the Minister of Health, 2018

Publication date: August 2018

This publication may be reproduced for personal or internal use only without permission provided the source is fully acknowledged.

Cat H167-2E-PDF

ISSN 2561-553X

Pub 180226

Table of Contents

TABLE OF CONTENTS	3
OVERVIEW	8
ACRONYMS	10
Submission Types	10
Documents	10
FEE CATEGORIES	11
NDS & SNDS	12
SUBMISSIONS RECEIVED	13
New Drug Submissions (NDS) Received by Fee Category	13
Supplemental New Drug Submissions (SNDS) Received by Fee Category	13
WORKLOAD	14
New Drug Submission (NDS) Review Workload / Backlog	14
Supplemental New Drug Submission (SNDS) Review Workload / Backlog	14
New Drug Submission (NDS) Review Workload by Fee Category	15
Supplemental New Drug Submission (SNDS) Review Workload by Fee Category	15
APPROVALS	16
New Drug Submission (NDS) Approvals by Fee Category and by NOC Type	16
Supplemental New Drug Submission (SNDS) Approvals by Fee Category & NOC Type	16
REVIEW CYCLE DECISIONS	18
New Drug Submission (NDS) Review Decisions	18
NDS - Review Cycle Completions Showing Percentage Within Target	18
Supplemental New Drug Submission (SNDS) Review Decisions	19
SNDS - Review Cycle Completions Showing Percentage Within Target	19
SCREENING CYCLE DECISIONS	20
New Drug Submission (NDS) Screening Decisions	20
NDS - Screening Cycle Completions Showing Percentage Within Target	20

Supplemental New Drug Submission (SNDS) Screening Decisions	21
SNDS - Screening Cycle Completions Showing Percentage Within Target	21
ANDS & SANDS	22
SUBMISSIONS RECEIVED	23
Abbreviated New Drug Submissions (ANDS) Received by Fee Category	23
Supplemental Abbreviated New Drug Submission (SANDS) Received by Fee Category	23
WORKLOAD	24
Abbreviated New Drug Submission (ANDS) Review Workload / Backlog	24
Supplemental Abbreviated New Drug Submission (SANDS) Review Workload / Backlog	24
Abbreviated New Drug Submission (ANDS) Review Workload by Fee Category	25
Supplemental Abbreviated New Drug Submission (SANDS) Review Workload by Fee Category	25
APPROVALS	26
Abbreviated New Drug Submission (ANDS) Approvals by Fee Category & NOC Type	26
Supplemental Abbreviated New Drug Submission (SANDS) Approvals by Fee Category and by NOC Type	26
REVIEW CYCLE DECISIONS	28
Abbreviated New Drug Submission (ANDS) Review Decisions	28
ANDS - Review Cycle Completions Showing Percentage Within Target	28
Supplemental Abbreviated New Drug Submission (SANDS) Review Decisions	29
SANDS - Review Cycle Completions Showing Percentage Within Target	29
SCREENING CYCLE DECISIONS	30
Abbreviated New Drug Submission (ANDS) Screening Decisions	30
ANDS - Screening Cycle Completions Showing Percentage Within Target	30
Supplemental Abbreviated New Drug Submission (SANDS) Screening Decisions	31
SANDS - Screening Cycle Completions Showing Percentage Within Target	31
PRIORITY REVIEW STATUS REQUESTS (FOR NDS & SNDS)	32
Priority Review Status Requests Received	32
Priority Review Status Requests: Decisions Rendered	33
Priority Review Status Requests: Performance	33
NOTIFIABLE CHANGES (NC)	34
SUBMISSIONS RECEIVED	35
Number Received - Notifiable Changes (NC) - by Class	35

Number Received - Notifiable Changes (Safety) – by Lead Bureau	35
WORKLOAD	36
Notifiable Change (NC) SAFETY: Review Workload / Backlog	36
Notifiable Change (NC) SAFETY: Review Workload by Class	36
PERFORMANCE	37
REVIEW Completions by Class - Notifiable Changes (NC)	37
SCREENING Completions by Class - Notifiable Changes (NC)	37
Decision Documents by Class - Notifiable Change (NC)	38
ADMINISTRATIVE SUBMISSIONS	39
Administrative Submissions Received by Submission Type (OSIP)	39
Administrative Submission Approvals (OSIP) for NDS, SNDS, ANDS and SANDS	39
CLINICAL TRIAL APPLICATIONS (CTA)	42
Number Received - Clinical Trial Application (CTA)	42
Number Received - Clinical Trial Application (CTA) - Excluding Bioequivalence (Generic)	42
Decision Documents - Clinical Trial Application (CTA)	43
Performance - Clinical Trials Applications (CTA) Reviews: 30 Day Target	43
Performance – CTA Review: 7 Day Administrative Target	43
CLINICAL TRIAL APPLICATION – AMENDMENTS (CTA-A)	44
Number Received - Clinical Trial Application-Amendments (CTA-A)	44
Decision Documents - Clinical Trial Application-Amendments (CTA-A)	44
Performance - Clinical Trial Application Amendments (CTA-A) Reviews: 30 Day Target	45
Performance - CTA-A: Reviews: 7 Day Administrative Target	45
DINA: APPLICATION FOR A DRUG IDENTIFICATION NUMBER	47
Number Received – DINA	47
WORKLOAD	48
Review Workload / Backlog - Showing Percentage in Backlog – DINA	48
Review Workload by Fee Category – DINA	48
Screening Workload / Backlog - Showing Percentage in Backlog – DINA	49
Screening Workload by Fee Category – DINA	49
DECISION DOCUMENTS	50
Decision Documents – DINA by Fee Category	50

PERFORMANCE.....	51
Performance Review Cycle Completions Showing Percentage Within Target – DINA	51
Performance Screening Cycle Completions Showing Percentage Within Target – DINA.....	51
 PDC: POST-AUTHORIZATION DIVISION 1 CHANGES, ...	52
Post-Authorization Division 1 Changes (PDC) Received	52
Post-Authorization Division 1 Changes (PDC) - Decision Documents by Class	52
 APPENDIX A: PRE-SUBMISSION MEETINGS	53
Pre-submission Meetings Held / Feedback Provided.....	53

This page is left blank intentionally.

OVERVIEW

The Therapeutic Products Directorate's (TPD) Quarterly Drug Submission Performance Report reflects pharmaceutical drug submission review activity over five consecutive quarters: from April - June 2017 to April - June 2018. Statistics are provided by Submission Type and show the number received, the number in workload, the number of decisions and the number of approvals.

General Information

There are several steps involved in the drug submission review¹ and approval process:

- administrative processing,
- regulatory and scientific screening and
- in-depth scientific review.

When deficiencies or non-compliance issues are found, a company may submit responses before a final decision can be reached and thus multiple review cycles may be required. A submission's approval time can vary depending on the number and type of review cycles needed.

Submissions Received are counts of submissions received during the year using the filing date (CR date) which is the date the submission is considered administratively complete by Health Canada.

Workload is the number of submissions “under active review” on the last day of the quarter. **“Backlog”** is the proportion of the workload that is over target. Often the term workload is used to mean the amount of work received over a period of time and is a common source of confusion.

Approvals² are Notice of Compliances (NOC) Issued or Issuable. An NOC issuable is when a submission's NOC is placed “on hold” awaiting authorization to market, due to Patented Medicines (NOC) Regulations or due to changes from Prescription to Non-Prescription.

¹ For further clarification refer to the [Guidance for Industry: Management of Drug Submissions](#).

² Final results from confirmatory trials submitted in the form of an SNDS-C are now included in the SNDS Received, Workload and Performance figures. SNDS-C are not included in the SNDS Approval figures. For further Clarification refer to the [Guidance Document: Notice of Compliance with Conditions \(NOC\)c](#).

A **review cycle completion**³ is counted upon the conclusion of an in-depth scientific review that then results in a decision of approval or non-approval. The time taken is compared to a set performance standard⁴ which is based on the type of submission, class and cycle (status). For example, in the case of a Priority NDS, the performance standard is 180 days for Review1 and 90 days for Review2. Health Canada has set a goal of 90% of review cycle completions to be rendered within performance standards.

"First Cycle Review" Approvals are those submissions approved without having to go through several review cycles to resolve submission deficiencies or non-compliance issues, and exclude "refiled"⁵ submissions.

Any questions or comments on this report should be forwarded to:

Office of Submissions and Intellectual Property, Therapeutic Products Directorate
Finance Building, A.L. # 0202A1
101 Tunney's Pasture Driveway, Tunney's Pasture
Ottawa, Ontario, K1A 0K9

Tel: (613) 941-7281 Fax: (613) 941-0825

Email: hc.osip-bppi.sc@canada.ca

³ Review cycles include all types e.g. Review 1, Review 2, Review QN. The total number of "review decisions" may surpass the total number of review cycle completions as they include cancellations/withdrawals that occur while the submission is 'inactive'. For example, a withdrawal can be issued when a company fails to respond to a notice of non-compliance within the allotted time frame. A 'Cancelled by Company' is counted as a review decision when a company sends a cancellation letter after the submission's original materials have been accepted for review.

⁴ Performance continues to be measured against performance standards for Submission Type/Submission Class/ Status combinations as set out in Appendix 3 of the Guidance for Industry: Management of Drug Submissions. This is not to be confused with the 'UF Review 1 (iteration 1)' performance standards that are employed to measure performance to meet the *User Fees Act* reporting Requirements in the 'Health Canada Departmental Performance Report (DPR)'.
⁵ For further clarification refer to the Guidance for Industry: Management of Drug Submissions

ACRONYMS

Submission Types

ANDS	- Abbreviated New Drug Submission
CTA	- Clinical Trial Application
CTA-A	- Clinical Trial Application-Amendment
DINA	- Application for a Drug Identification Number
DIND	- Application for a Drug Identification Number – Disinfectant Product
DINF	- Application for a Drug Identification Number - Category IV Product – (Labelling Standard)
NDS	- New Drug Submission
NC	- Notifiable Change – New Drug
PDC	- Post-DIN Changes
PRNDS	- Request for Priority Review Status: New Drug Submission
PRSNDS	- Request for Priority Review Status: Supplemental New Drug Submission
SANDS	- Supplemental Abbreviated New Drug Submission
SNDS	- Supplemental New Drug Submission
SNDS-C	- Supplemental New Drug Submission – CONFIRMATORY

Documents

NOC	- Notice of Compliance
NOC-c	- Notice of Compliance with Conditions
Issuable NOC (Patent)	- NOC on Hold due to Patented Medicines (NOC) Regulations
Issuable NOC (Rx to OTC)	- NOC on Hold due to changes (Prescription to Non-Prescription)
NON	- Notice of Non-Compliance
NOD	- Notice of Deficiency
NON Withdrawal	- Notice of Non-Compliance Withdrawal Letter
NOD Withdrawal	- Notice of Deficiency Withdrawal Letter

Fee Categories

Fee Category	Fee Category Description
New Active Substance (NAS)	Submission in support of a drug, excluding a disinfectant, that contains a medicinal ingredient not previously approved in a drug for sale in Canada, and that is not a variation of a previously approved medicinal ingredient such as a salt, ester, enantiomer, solvate or polymorph. For biologics, this submission class does not include an NDS in support of a subsequent entry biologic or an SNDS in support of changes to the manufacturing process of biologics.
Clinical or Non-Clinical Data and Chemistry and Manufacturing data	Submissions based on clinical or non-clinical data and chemistry and manufacturing data for a drug that does not include a NAS.
Clinical or Non-Clinical Data Only	Submissions based only on clinical or non-clinical data for a drug that does not include a NAS.
Comparative Studies	Submissions based on comparative studies with or without chemistry and manufacturing data for a drug that does not include a NAS. It excludes superiority and non-inferiority studies since they are clinical studies. It also excludes pharmaceutical equivalence studies since they are captured by the chemistry and manufacturing fee.
Chemistry and Manufacturing Data Only	Submissions based only on chemistry and manufacturing data for a drug that does not include a NAS.
Published Data Only	Submissions based only on published clinical or non-clinical data for a drug that does not include a NAS.
Switch from Prescription to Nonprescription Status	Submissions based only on data that support the modification or removal of a medicinal ingredient on the Prescription Drug List . This fee is limited to switches from prescription to nonprescription status when an identical claim is made for an existing drug.
Labelling Only⁶	Submissions of labelling material that do not include supporting clinical or non-clinical data or chemistry and manufacturing data.
Administrative Submission⁷	Submissions in support of a manufacturer or product name change.
Disinfectants⁸	Submissions and applications that include data in support of a disinfectant.
Drug Identification Number (DIN) - Labelling Standards	Applications attesting to compliance with a labelling standard or Category IV Monograph (DINF) for a drug that does not include clinical or non-clinical data or chemistry and manufacturing data.

For further information, please refer to the [Guidance Document - Fees for the Review of Drug Submissions and Applications](#)

⁶ For more information, please consult the [Guidance Document: Question and Answers about Plain Language Labelling](#)



⁷ For additional information, please consult the ["Changes in Manufacturer and/or Product Name Policy" \(2015\)](#)

⁸ The non-prescription (or over-the-counter) and disinfectant drug review functions were moved from TPD to the Natural and Non-prescription Health Products Directorate (NNHPD) on July 1, 2013. These products are reported on in a separate NNHPD Drug Submission Performance Report.



**New Drug Submission
(NDS)**

&

**Supplemental New Drug Submission
(SNDS)**

SUBMISSIONS RECEIVED**New Drug Submissions (NDS) Received by Fee Category****Supplemental New Drug Submissions (SNDS) Received by Fee Category**

⁹ Submissions granted Priority Review Status or found eligible for advance NOC/e consideration are assigned a shortened review target to account for the Priority nature of the submission. For further clarification, please see the [Priority Review of Drug Submissions Policy](#), the [Notice of Compliance with conditions \(NOC/e\) Guidance](#) and the [Management of Drug Submissions Guidance](#).



WORKLOAD**New Drug Submission (NDS) Review Workload / Backlog****Supplemental New Drug Submission (SNDS) Review Workload / Backlog**

WORKLOAD**New Drug Submission (NDS) Review Workload by Fee Category**

TPD NDS All REVIEW WORKLOAD BY FEE CATEGORY AND END OF QUARTER					
	2017-06-30	2017-09-30	2017-12-31	2018-03-31	2018-06-30
Labelling Only	4	2	3	4	4
Backlog	0	0	0	0	0
Comparative Studies	2	3	1	1	1
Backlog	0	1	0	0	0
Chemistry & Manufacturing	0	0	1	1	0
Backlog	0	0	0	0	0
Clinical or Non-Clin Only	0	0	0	0	0
Backlog	0	0	0	0	0
Clinical or Non-Clin and C&M	23	24	20	18	16
Backlog	0	3	2	0	0
New Active Substance	14	13	20	25	27
Backlog	1	1	1	0	1
Total	43	42	45	49	48
Non Backlog	42	37	42	49	47
Backlog	1	5	3	0	1
% in Backlog	2%	12%	7%	0%	2%
Priority (subset)	5	3	3	6	7
Backlog	0	0	0	0	0

Supplemental New Drug Submission (SNDS) Review Workload by Fee Category

TPD SNDS All REVIEW WORKLOAD BY FEE CATEGORY AND END OF QUARTER					
	2017-06-30	2017-09-30	2017-12-31	2018-03-31	2018-06-30
Labelling Only	23	23	28	19	15
Backlog	1	2	0	0	1
Comparative Studies	7	8	4	4	8
Backlog	0	0	0	0	0
Chemistry & Manufacturing	37	38	34	30	26
Backlog	0	2	1	0	0
Clinical or Non-Clin Only	55	53	63	63	60
Backlog	1	1	0	0	0
Clinical or Non-Clin and C&M	5	6	9	11	13
Backlog	0	0	0	0	0
Published Data	8	5	8	10	9
Backlog	0	0	0	0	0
Total	135	133	146	137	131
Non Backlog	133	128	145	137	130
Backlog	2	5	1	0	1
% in Backlog	1%	4%	1%	0%	1%
Priority (subset)	2	2	5	7	7
Backlog	0	0	0	0	0
SNDS-C (Confirmatory)	7	6	5	3	2
Backlog	0	0	0	0	0


APPROVALS¹⁰**New Drug Submission (NDS) Approvals by Fee Category and by NOC Type****Supplemental New Drug Submission (SNDS) Approvals by Fee Category & NOC Type**

¹⁰ Submissions granted Priority Review Status or found eligible for advance NOC/e consideration are assigned a shortened review target to account for the Priority nature of the submission. For further clarification, please see the [Priority Review of Drug Submissions Policy](#), the [Notice of Compliance with conditions \(NOC/e\) Guidance](#) and the [Management of Drug Submissions Guidance](#).


This page is left blank intentionally.

REVIEW CYCLE DECISIONS

New Drug Submission (NDS) Review Decisions




NDS - Review Cycle Completions Showing Percentage Within Target




REVIEW CYCLE DECISIONS

Supplemental New Drug Submission (SNDS) Review Decisions




SNDS - Review Cycle Completions Showing Percentage Within Target




SCREENING CYCLE DECISIONS

New Drug Submission (NDS) Screening Decisions




NDS - Screening Cycle Completions Showing Percentage Within Target




SCREENING CYCLE DECISIONS

Supplemental New Drug Submission (SNDS) Screening Decisions





SNDS - Screening Cycle Completions Showing Percentage Within Target





**Abbreviated New Drug Submissions
(ANDS)**

&

**Supplemental Abbreviated New Drug Submissions
(SANDS)**

SUBMISSIONS RECEIVED**Abbreviated New Drug Submissions (ANDS) Received by Fee Category****Supplemental Abbreviated New Drug Submission (SANDS) Received by Fee Category**

WORKLOAD**Abbreviated New Drug Submission (ANDS) Review Workload / Backlog****Supplemental Abbreviated New Drug Submission (SANDS) Review Workload / Backlog**

WORKLOAD**Abbreviated New Drug Submission (ANDS) Review Workload by Fee Category**


TPD ANDS ALL REVIEW WORKLOAD BY FEE CATEGORY AND END OF QUARTER					
	2017-06-30	2017-09-30	2017-12-31	2018-03-31	2018-06-30
Chemistry & Manufacturing	46	46	49	43	45
<i>Backlog</i>	5	5	4	2	1
Comparative Studies	73	79	73	65	68
<i>Backlog</i>	7	6	6	2	0
Labelling Only	2	1	2	3	0
<i>Backlog</i>	0	0	0	0	0
Total	121	126	124	111	113
Non Backlog	109	115	114	107	112
BACKLOG	12	11	10	4	1
% in Backlog	10%	9%	8%	4%	1%

Supplemental Abbreviated New Drug Submission (SANDS) Review Workload by Fee Category


TPD SANDS ALL REVIEW WORKLOAD BY FEE CATEGORY AND END OF QUARTER					
	2017-06-30	2017-09-30	2017-12-31	2018-03-31	2018-06-30
Chemistry & Manufacturing	26	38	27	26	24
<i>Backlog</i>	1	2	1	0	0
Clinical or Non-Clin Only	0	0	0	0	0
<i>Backlog</i>	0	0	0	0	0
Comparative Studies	2	3	0	2	2
<i>Backlog</i>	0	1	0	0	0
Published Data	1	1	1	0	0
<i>Backlog</i>	0	0	0	0	0
Labelling Only	14	28	15	19	18
<i>Backlog</i>	1	1	0	0	0
Total	43	70	43	47	44
Non Backlog	41	66	42	47	44
BACKLOG	2	4	1	0	0
% in Backlog	5%	6%	2%	0%	0%

APPROVALS

Abbreviated New Drug Submission (ANDS) Approvals by Fee Category & NOC Type




Supplemental Abbreviated New Drug Submission (SANDS) Approvals by Fee Category and by NOC Type




This page is left blank intentionally.

REVIEW CYCLE DECISIONS

Abbreviated New Drug Submission (ANDS) Review Decisions




ANDS - Review Cycle Completions Showing Percentage Within Target




REVIEW CYCLE DECISIONS

Supplemental Abbreviated New Drug Submission (SANDS) Review Decisions




SANDS - Review Cycle Completions Showing Percentage Within Target




SCREENING CYCLE DECISIONS

Abbreviated New Drug Submission (ANDS) Screening Decisions




ANDS - Screening Cycle Completions Showing Percentage Within Target




SCREENING CYCLE DECISIONS

Supplemental Abbreviated New Drug Submission (SANDS) Screening Decisions




SANDS - Screening Cycle Completions Showing Percentage Within Target




Priority Review Status Requests (for NDS & SNDS)


Priority Review Status Requests Received



Priority Review Status Requests: Decisions Rendered



Priority Review Status Requests: Performance




NOTIFIABLE CHANGES (NC)


NOTIFIABLE CHANGES¹¹

SUBMISSIONS RECEIVED


Number Received - Notifiable Changes (NC) - by Class





Number Received - Notifiable Changes (Safety) – by Lead Bureau



¹¹ In February 2013 the Safety Labelling Changes to the Product Monographs of Brand Name Pharmaceutical Drug Products process was introduced to inform generic drug manufacturers about new safety information for pharmaceutical drug products so that they can update their PMs for health care professionals and Canadians.

WORKLOAD**Notifiable Change (NC) SAFETY: Review Workload / Backlog****Notifiable Change (NC) SAFETY: Review Workload by Class**

TPD NC - SAFETY: REVIEW WORKLOAD AT END OF QUARTER					
FEE Category	2017-06-30	2017-09-30	2017-12-31	2018-03-31	2018-06-30
SAFETY - 90 day	161	206	181	184	145
Backlog	69	70	43	39	23
SAFETY - 120 day	33	26	35	22	26
Backlog	7	5	5	3	2
Total	194	232	216	206	171
Non Backlog	118	157	168	164	146
BACKLOG	76	75	48	42	25
% in Backlog	39%	32%	22%	20%	15%

PERFORMANCE**REVIEW Completions by Class - Notifiable Changes (NC)****SCREENING Completions by Class - Notifiable Changes (NC)**

Decision Documents by Class - Notifiable Change (NC)


NC - SAFETY (90)					
DOCUMENT TYPE	Apr-Jun 2017	Jul-Sep 2017	Oct-Dec 2017	Jan-Mar 2018	Apr-Jun 2018
NO OBJECTION LETTER	241	255	262	232	273
NOT SATISFACTORY NOTICE	0	0	0	0	0
REJECTION LETTER (SCR)	0	2	0	1	0
SCREENING DEFICIENCY NOTICE	41	44	40	36	40
CANCELLED BY COMPANY	17	20	18	11	25
NC - HOLD (PATENT)	16	11	3	16	6
SPONSOR SUB CHANGE ACCEPT	0	0	0	0	0

NC - SAFETY (120)					
DOCUMENT TYPE	Apr-Jun 2017	Jul-Sep 2017	Oct-Dec 2017	Jan-Mar 2018	Apr-Jun 2018
NO OBJECTION LETTER	14	22	24	30	15
NOT SATISFACTORY NOTICE	0	0	0	0	0
SCREENING DEFICIENCY NOTICE	2	4	8	6	6
CANCELLED BY COMPANY	5	1	1	1	2
REJECTION LETTER (SCR)	0	0	0	0	0


Administrative Submissions

(Product & Manufacturer Name Changes¹²)

Administrative Submissions Received by Submission Type (OSIP)



Administrative Submission Approvals (OSIP) for NDS, SNDS, ANDS and SANDS



¹² For additional information, please consult the "Changes in Manufacturer and/or Product Name Policy" (2015)


This page is left blank intentionally.

Clinical Trial Applications and Amendments


(CTA & CTA-A)

Clinical Trial Applications (CTA)

Number Received - Clinical Trial Application (CTA)



Number Received - Clinical Trial Application (CTA) - Excluding Bioequivalence (Generic)




DECISION DOCUMENTS

Decision Documents - Clinical Trial Application (CTA)


CTA					
DOCUMENT TYPE	Apr-Jun 2017	Jul-Sep 2017	Oct-Dec 2017	Jan-Mar 2018	Apr-Jun 2018
NO OBJECTION LETTER	234	238	237	189	208
CANCELLED BY COMPANY	15	9	20	20	12

PERFORMANCE

Performance - Clinical Trials Applications (CTA) Reviews: 30 Day Target




Performance – CTA Review: 7 Day Administrative Target



Clinical Trial Application – Amendments (CTA-A)



Number Received - Clinical Trial Application-Amendments (CTA-A)



DECISION DOCUMENTS

Decision Documents - Clinical Trial Application-Amendments (CTA-A)

CTA-A (excluding administrative)					
DOCUMENT TYPE	Apr-Jun 2017	Jul-Sep 2017	Oct-Dec 2017	Jan-Mar 2018	Apr-Jun 2018
NO OBJECTION LETTER	290	245	252	250	280
CANCELLED BY COMPANY	3	1	5	3	8
NOT SATISFACTORY NOTICE	1	0	0	0	0

PERFORMANCE**Performance - Clinical Trial Application Amendments (CTA-A) Reviews: 30 Day Target****Performance - CTA-A: Reviews: 7 Day Administrative Target**


DINA

Application for a Drug Identification Number

The non-prescription (or over-the-counter) and disinfectant drug review functions were moved from TPD to the Natural and Non-prescription Health Products Directorate (NNHPD) on July 1, 2013. These products are reported in a separate NNHPD Drug Submission Performance Report as of October 1, 2015.

DINA: Application for a Drug Identification Number¹³


Number Received – DINA



¹³ The non-prescription (or over-the-counter) and disinfectant drug review functions were moved from TPD to the Natural and Non-prescription Health Products Directorate (NNHPD) on July 1, 2013. These products are reported in a separate NNHPD Drug Submission Performance Report as of October 1, 2015.

REVIEW WORKLOAD

Review Workload / Backlog - Showing Percentage in Backlog – DINA




Review Workload by Fee Category – DINA

TPD DINA All REVIEW WORKLOAD BY FEE CATEGORY AND END OF QUARTER					
	2017-06-30	2017-09-30	2017-12-31	2018-03-31	2018-06-30
Labelling Only	18	20	14	13	19
Backlog	1	0	1	1	1
Chemistry & Manufacturing	12	14	17	19	15
Backlog	0	1	1	0	0
Published Data	0	0	1	1	0
Backlog	0	0	0	0	0
Clinical or Non-Clin and C&M	0	0	0	0	4
Backlog	0	0	0	0	0
Comparative Studies	1	2	1	1	4
Backlog	0	0	0	0	0
Total	31	36	33	34	42
Non Backlog	30	35	31	33	41
BACKLOG	1	1	2	1	1
% in Backlog	3%	3%	6%	3%	2%

SCREENING WORKLOAD

Screening Workload / Backlog - Showing Percentage in Backlog – DINA



Screening Workload by Fee Category – DINA

TPD DINA ALL SCREENING WORKLOAD BY FEE CATEGORY AND END OF QUARTER					
	2017-06-30	2017-09-30	2017-12-31	2018-03-31	2018-06-30
Labelling Only	4	3	3	8	3
Backlog	0	0	0	0	0
Labelling Standard	0	0	0	0	0
Backlog	0	0	0	0	0
Clinical or Non-Clin and C&M	0	0	2	2	0
Backlog	0	0	1	0	0
Chemistry & Manufacturing	1	3	10	4	4
Backlog	0	0	1	0	0
Published Data	0	1	0	0	0
Backlog	0	0	0	0	0
Comparative Studies	1	0	0	2	0
Backlog	0	0	0	0	0
Total	6	7	15	16	7
Non Backlog	6	7	13	16	7
BACKLOG	0	0	2	0	0
% in Backlog	0%	0%	13%	0%	0%

DECISION DOCUMENTS

Decision Documents – DINA by Fee Category



DINA - Labelling Only					
DOCUMENT TYPE	Apr-Jun 2017	Jul-Sep 2017	Oct-Dec 2017	Jan-Mar 2018	Apr-Jun 2018
NOTIFICATION FORM/DIN ISSUED	3	1	5	3	1
NO OBJECTION LETTER	9	4	6	6	5
CANCELLED BY COMPANY	1	0	0	2	3
DIN INCORR SUBTYPE-CLASS	0	0	0	0	0
NEW DRUG LETTER SCREEN	0	0	0	0	0
NON WITHDRAWAL LETTER	0	0	0	0	0
NOTICE OF DEFICIENCY	0	0	0	0	0
NOTICE OF NON-COMPLIANCE	0	0	0	0	2
REJECTION LETTER (SCR)	0	0	1	0	0
SCREENING DEFICIENCY NOTICE	1	3	1	3	2
SPONSOR SUB CHANGE ACCEPT	0	0	0	0	0


DINA - CHEMISTRY AND MANUFACTURING					
DOCUMENT TYPE	Apr-Jun 2017	Jul-Sep 2017	Oct-Dec 2017	Jan-Mar 2018	Apr-Jun 2018
NOTIFICATION FORM/DIN ISSUED	3	2	4	4	4
NO OBJECTION LETTER	0	2	0	1	3
NOD WITHDRAWAL LETTER	0	0	0	0	0
NON WITHDRAWAL LETTER	1	0	0	1	0
NOTICE OF DEFICIENCY	0	0	0	2	0
NOTICE OF NON-COMPLIANCE	2	2	1	1	1
NEW DRUG LETTER REVIEW	1	0	0	0	0
NEW DRUG LETTER SCREEN	0	0	0	0	0
REJECTION LETTER (SCR)	0	0	0	0	0
SCREENING DEFICIENCY NOTICE	1	2	0	6	3
CANCELLED BY COMPANY	0	0	0	3	1

DINA - PUBLISHED DATA ONLY					
DOCUMENT TYPE	Apr-Jun 2017	Jul-Sep 2017	Oct-Dec 2017	Jan-Mar 2018	Apr-Jun 2018
SCREENING DEFICIENCY NOTICE	0	1	0	0	0
NO OBJECTION LETTER	0	0	0	0	1
REJECTION LETTER (SCR)	0	0	0	0	0
NOTICE OF DEFICIENCY	0	0	0	0	0
NOTICE OF NON-COMPLIANCE	0	0	0	0	0
CANCELLED BY COMPANY	0	0	0	0	0
NON WITHDRAWAL LETTER	0	0	0	0	0
NOT SATISFACTORY NOTICE	0	0	0	0	0

DINA - COMPARATIVE STUDIES					
DOCUMENT TYPE	Apr-Jun 2017	Jul-Sep 2017	Oct-Dec 2017	Jan-Mar 2018	Apr-Jun 2018
NOTIFICATION FORM/DIN ISSUED	0	0	0	1	0
NOTICE OF DEFICIENCY	0	0	0	0	0
NOTICE OF NON-COMPLIANCE	0	0	1	0	0
NO OBJECTION LETTER	0	0	0	0	0
SCREENING DEFICIENCY NOTICE	2	0	0	1	1

DINA - CLINICAL OR NON CLINICAL DATA AND C&M					
DOCUMENT TYPE	Apr-Jun 2017	Jul-Sep 2017	Oct-Dec 2017	Jan-Mar 2018	Apr-Jun 2018
CANCELLED BY COMPANY	0	0	0	1	0
SCREENING DEFICIENCY NOTICE	0	0	0	2	2

PERFORMANCE**Performance Review Cycle Completions Showing Percentage Within Target – DINA****Performance Screening Cycle Completions Showing Percentage Within Target – DINA**

PDC: Post-Authorization Division 1 Changes,¹⁴**Post-Authorization Division 1 Changes (PDC) Received****Post-Authorization Division 1 Changes (PDC) - Decision Documents by Class**


PDC					
DOCUMENT TYPE	Apr-Jun 2017	Jul-Sep 2017	Oct-Dec 2017	Jan-Mar 2018	Apr-Jun 2018
REGULAR					
CANCELLED BY COMPANY	3	3	5	4	3
NO OBJECTION LETTER	9	2	9	15	30
NOT SATISFACTORY NOTICE	0	0	0	0	0
REJECTION LETTER (SCR)	0	0	0	0	0

¹⁴ The non-prescription (or over-the-counter) and disinfectant drug review functions were moved from TPD to the Natural and Non-prescription Health Products Directorate (NNHPD) on July 1, 2013. These products are reported in a separate NNHPD Drug Submission Performance Report as of October 1, 2015.

Appendix A: Pre-submission Meetings

15

Pre-submission Meetings Held / Feedback Provided



¹⁵ Prior to filing a submission, the sponsor may request a pre-submission meeting to discuss the presentation of data in support of the submission. For further information, refer to the [Management of Drug Submissions Guidance](#)